Kansas Senate Bill SB322

Kansas 2025-2026 Regular Session

• Introduced: 1/14/26
• Refer: 1/15/26
• Report Pass: 2/3/26
• Engrossed: 2/11/26
• Refer: 2/11/26
• Refer: 3/11/26

Caption

Removing the authority of the state board of pharmacy to authorize individuals to access the prescription monitoring program database by rules and regulations.

Summary

SB 322 amends Kansas’s Prescription Monitoring Program Act to remove one specific source of authority for access to the program database. Under current law, the state board of pharmacy may, by rule and regulation, authorize additional individuals to access the database as delegates. The bill strikes that third delegate category from the statute, leaving only the expressly listed delegate groups: certain health care personnel acting as agents of practitioners or pharmacists, and death investigators acting as agents of medical examiners, coroners, or other authorized persons. The measure is a narrow administrative-rules bill focused on limiting how access to prescription monitoring data can be expanded. It does not change the core operation of the prescription monitoring program, the definition of scheduled substances, or the reporting framework for dispensers. Instead, it constrains the board’s ability to broaden database access through rulemaking and repeals the existing statutory language that granted that authority.

Impact

SB 322 would amend K.S.A. 2025 Supp. 65-1682, the definitional section of the Prescription Monitoring Program Act, and repeal the prior version of that section. Its practical effect is to remove the board of pharmacy’s discretion to authorize additional delegate access to the prescription monitoring database by regulation, which may reduce administrative flexibility but also narrows who can be granted access to sensitive prescription data. The bill affects the state board of pharmacy, practitioners, pharmacists, designated health care delegates, and death investigators who use the database for monitoring controlled substances and drugs of concern.

Sentiment

The available voting history suggests strong, bipartisan support and little controversy: the Senate Consent Calendar passed SB 322 unanimously, 40-0. No committee transcript is provided, but the unanimous vote indicates the bill was viewed as a routine or noncontroversial administrative change rather than a major policy shift. The absence of recorded opposition or amendment debate suggests general agreement with tightening the statutory basis for database access.

Contention

The main point of potential contention is the removal of the board of pharmacy’s rulemaking authority to authorize additional database delegates. Supporters would likely view this as a needed statutory clarification and a way to keep access to prescription monitoring data tightly controlled. Any concern would come from stakeholders who value administrative flexibility—such as the board, practitioners, or program administrators—because the change could limit the board’s ability to adapt access rules to new roles or operational needs without further legislation.